Inhibrx Biosciences is advancing ozekibart in Ewing sarcoma, deepening its push into a rare cancer with high unmet need. The company is running a Phase 1/2 trial and has expanded evaluation into new cohorts, including colorectal adenocarcinoma.
published
Inhibrx Biosciences is advancing ozekibart in Ewing sarcoma, deepening its push into a rare cancer with high unmet need. The company is running a Phase 1/2 trial and has expanded evaluation into new cohorts, including colorectal adenocarcinoma.
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.